[Application of quantitative proteomic analysis for cancer therapy using "reverse-phase" protein lysate microarrays].
Proteomic analysis using quantitative high-throughput technology can provide new insights in cancer therapeutics. It can reveal how cancer cells respond to given therapies by measuring multiple dimensions of information, from which dynamic proteomic responses can be observed. A lack of high throughput proteomic technologies has previously limited such multi-dimensional approaches. We have developed a high-throughput, "reverse-phase" protein microarray system which can handle more than 20,000 lysate features on a single glass slide. Subsequent immunochemical detection methods allow us to monitor protein expression in a quantitative manner as a function of both time and drug dosage. The data generated using this RPA technology has proved to be an excellent reference for theoretical protein network modeling in vitro. Clinical evaluation of drug efficacy based on the data generated by this technology may provide a means to accurately predict the effectiveness of cancer therapies.
Nishizuka
Satoshi
S
Molecular Translational Technology, Molecular Therapeutics Program, National Cancer Institute, National Institutes of Health, USA.
Spurrier
Brett
B
Honkanen
Peter
P
Austin
John
J
Wakabayashi
Go
G
D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy*; D040081:Protein Array Analysis / Q000295:instrumentation* / Q000379:methods*; D040901:Proteomics / Q000295:instrumentation* / Q000379:methods*